Current Report Filing (8-k)
August 06 2018 - 5:11PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): August 6, 2018
SELLAS Life Sciences Group, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-33958
|
|
20-8099512
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
15 West 38th Street, 10th Floor
New York, NY 10018
(Address of Principal Executive Offices) (Zip Code)
Registrants telephone number, including area
code: (917) 438-4353
315 Madison Avenue, 4
th
Floor
New York, New York 10017
(Former name or former address, if changed since last report)
Check the appropriate box below if
the Form 8-K filing
is intended to simultaneously satisfy the filing
obligations of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to
Rule 14a-12 under
the
Exchange Act (17
CFR 240.14a-12)
|
☐
|
Pre-commencement communications
pursuant to
Rule 14d-2(b) under
the Exchange Act (17
CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications
pursuant to
Rule 13e-4(c) under
the Exchange Act (17
CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this
chapter) or
Rule 12b-2 of
the Securities Exchange Act of 1934
(§ 240.12b-2 of
this chapter).
Emerging growth company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
SELLAS Life Sciences Group, Inc. (the Company) is filing this information for the sole purpose of confirming the Companys
compliance with the continued listing standards of the Nasdaq Stock Market (Nasdaq). The Company has not received any correspondence from Nasdaq that it is not in compliance with any applicable Nasdaq listing rules.
On July 16, 2018, as previously announced, the Company consummated an underwritten public offering (the Offering) of
6,845,000 shares of common stock, 4,675,000
pre-funded
warrants exercisable for shares of common stock and accompanying common stock warrants to purchase an aggregate of 11,520,000 shares of common stock. The
Company received net proceeds from the Offering of approximately $21.6 million, after deducting underwriting discounts and commissions and estimated offering expenses.
As of the date of this Current Report on Form
8-K
and as a result of the consummation of the Offering,
the Company believes that it is in compliance with Nasdaq Listing Rule 5550(b)(1) because the Companys stockholders equity is greater than $2,500,000.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
SELLAS Life Sciences Group, Inc.
|
|
|
|
|
Dated: August 6, 2018
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Barbara A. Wood
|
|
|
|
|
|
|
Barbara A. Wood
|
|
|
|
|
|
|
General Counsel and Executive Vice President
|
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Mar 2024 to Apr 2024
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Apr 2023 to Apr 2024